Healthcare policy conversations are starting to converge

PBM reform.
Break Up Big Medicine proposals.
Pricing codification efforts.

Individually, each looks like a discrete initiative.

Collectively, they signal something more important.

To me, this is a gradual rebalancing of leverage across the healthcare distribution system.

For the last decade, consolidation and rebate architecture concentrated negotiating power in predictable places. That structure created efficiencies for some — and real pressure for others.

Now we’re seeing policy threads that, taken together, may begin shifting contracting incentives, rebate dynamics, and pricing assumptions over the next 12–24 months.

This isn’t about one bill or one reform.

It’s about incentives.

When leverage shifts, distribution strategy shifts.

When distribution shifts, pricing architecture adjusts.

The leaders who think structurally aren’t reacting to headlines; they’re stress-testing their assumptions.

Remember — don’t chase the headlines.

Previous
Previous

In Pharmaceutical Executive: Ron Lanton on the FDA’s Changing Clinical Trial Framework

Next
Next

The Consolidated Appropriations Act of 2026 is a reminder that legal risk rarely shows up all at once.